A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PASDAS / Psoriatic Arthritis Disease Activity Score

[Related PubMed/MEDLINE]
Total Number of Papers: 39
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PASDAS  (>> Co-occurring Abbreviation)
Long Form:   Psoriatic Arthritis Disease Activity Score
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthritis. MCV, MIC, SEM
2022 Determinants of work and social participation in patients with psoriatic arthritis in the Netherlands: an observational study. LDA, PsA, WFP
2022 Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies. DSS, FACIT-F, HAQ-DI, MCS, PCS, PF, PROs, PsA, SF-36, WLQ
2022 Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. DAPSA, LDA, MDA, VLDA
2022 Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial. BSA, DAPSA, EI, LDA, LDI, LEI, MDA, mNAPSI, PsA, SPARCC
2022 Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. ACR20, ETN, MDA, MTX, PsA, VLDA
2022 Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. FACIT-F, HAQ-DI, MDA
2021 Development of an Instrument for Patient Self-assessment in Psoriatic Arthritis. COVID-19, HCP, PsA
2021 Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. CPDAI, DAPSA, FLARE, GRAPPA, ICC, PsA
10  2021 Performance of 3 Composite Measures for Disease Activity in Peripheral Spondyloarthritis. ASDAS, DAPSA, PsO, pSpA
11  2021 Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. FACIT-F, MDA, Pain VAS, PROs, PsA
12  2021 Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia. CPDAI, DAPSA, FMS, PsA, US
13  2020 Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). ACR, DAPSA, DMARD, HAQ, LEF, MDA, MTX, PsA, PSAID, SF-12
14  2020 Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial. CDAI, DAPsA, MDA, PsA, VLDA
15  2020 Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden. HDA, MDA
16  2020 Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. CDAI, DAPSA, MDA, PsA, SDAI, VLDA
17  2019 Comparison of disease activity measures in early psoriatic arthritis in usual care. CPDAI, DAPSA, DAS28, DEPAR, ES, GRACE, HRQoL, MDA, SRM
18  2019 Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. DAPSA, mCPDAI, PsA
19  2019 Development of a Modified Psoriatic Arthritis Disease Activity Score Using the Medical Outcomes Study Short Form 12 as a Measure of Quality of Life. mPASDAS, PsA, SF-36
20  2019 Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. ADA, DAPSA, MDA, PBO, TA
21  2019 The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. AUC, DAPSA, PASS
22  2019 Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity. MDA, PsA, ROC
23  2018 Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. CPDAI, DAPSA, MDA, OPAL, PsA, TNFi
24  2018 Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. HDA, HRQoL, LDA, PROs, PsA, TNFi
25  2017 Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort. bDMARD, cDAPSA, csDMARD, DAPSA, LDA, MDA, PsA
26  2017 Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS). ---
27  2017 Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. CASPAR, CPDAI, DAPSA, DAS28, DLQI, ESR, MDA, PASI, PsA, SDAI
28  2017 Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity. DAPSA, PsA
29  2017 The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. AUC, CPDAI, GRAPPA, PsA, SC, TC, TICOPA
30  2017 The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. GOL, MTX, PsA
31  2017 Ultrasonographic Enthesopathy and Disease Activity in Psoriatic Arthritis. PsA
32  2017 Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. DAPSA, LOPAS II, MDA, PsA, RAPID3, TICOPA, VAS, VLDA
33  2016 Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. CPDAI, DAPSA, MDA, PD, PsA, US
34  2015 Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments. CPDAI, MDA
35  2014 Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. CPDAI, GRACE, PsA
36  2014 Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. CPDAI, CRP, DAPSA, ESR, HAQ, MDA, PASI, SDAI
37  2014 Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. DAPSA, ESR, PASI, PsA, WBC
38  2013 Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. AMDF, CPDAI, DAPSA, DAS28
39  2012 Classification and clinical assessment. AS, PASI, PASRI, PsA